Suchergebnisse - (Person:"Curtin, Nicola")

PubPharm (228)

81

PARP Inhibitors for Cancer Therapy

Erschienen: [s.l.], Humana Press, 2015

Cancer Drug Discovery and Development - 83

von Curtin, N. | Sharma, R.

82

PARP Inhibitors for Cancer Therapy

Erschienen: Cham, Springer International Publishing AG, 2015

Cancer Drug Discovery and Development Ser.

von Curtin, N. | Sharma, R.

83

DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival

enthalten in: Clinical cancer research | 2015

von Cornell, L. | Munck, J. | Alsinet, C. | +13

84

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System

enthalten in: Molecular cancer therapeutics | 2015

von Parrish, K. | Cen, L. | Murray, J. | +11

85

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma

enthalten in: Current opinion in oncology | 2014

von Vormoor, B. | Curtin, N.

86

PARP inhibitors for anticancer therapy

enthalten in: Biochemical Society transactions | 2014

von Curtin, N.

87

DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin

enthalten in: Breast cancer research and treatment | 2014

von Ciszewski, W. | Tavecchio, M. | Dastych, J. | +1

88

PARP inhibitors target ATM+p53-defective gastric cancer

enthalten in: Cell cycle (Georgetown, Tex.) | 2014

von Curtin, N.

CommentOn: Cell Cycle. 2014;13(13):2129-37. - PMID 24841718

89

The use of ovarian cancer cells from patients undergoing surgery to generate primary cultures capable of undergoing functional analysis

enthalten in: PloS one | 2014

von O Donnell, R. | McCormick, A. | Mukhopadhyay, A. | +9

90

PARP inhibitors for anticancer therapy

enthalten in: Biochemical Society transactions | 2014

von Curtin, N.